Retatrutide: Mechanism, Research & UK Safety Profile
Also known as: LY3437943, triple agonist GLP-1/GIP/glucagon
A once-weekly triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly, demonstrating mean body-weight reductions of approximately 24% at 48 weeks in Phase 2 research.
Molecular formula
C₂₂₄H₃₄₁N₄₇O₆₈S
Molecular weight
4930 Da (approximate)
Half-life
Approximately 6 days, consistent with the C-20 fatty diacid–albumin binding strategy; this extended half-life supports once-weekly dosing and produces stable plasma concentrations within 4–5 weeks at any given dose level.
Category
GLP-1/GIP Agonists
Overview
Retatrutide (LY3437943) is a novel synthetic peptide developed by Eli Lilly and Company that acts simultaneously as an agonist at three distinct receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-receptor agonism—sometimes termed a "triagonist" or "triple incretin"—represents the current frontier of incretin-based pharmacology and has produced the largest pharmacologically induced weight-loss results reported in any human clinical trial to date.
Phase 2 clinical data published in The New England Journal of Medicine in 2023 demonstrated that retatrutide at its highest studied dose (12 mg once weekly) produced a mean weight reduction of approximately 24.2% from baseline at 48 weeks in adults with obesity. Notably, the weight-loss trajectory had not reached a plateau by the end of the trial, suggesting that maximum efficacy may not yet have been achieved at that timepoint. These results substantially exceeded those observed with tirzepatide (approximately 22.5% at 72 weeks in SURMOUNT-1) and semaglutide (approximately 15% at 68 weeks in STEP 1), positioning retatrutide as the most potent metabolic peptide in late-stage development.
The addition of glucagon receptor agonism to the dual GIP/GLP-1 profile of tirzepatide is hypothesised to confer additional energy expenditure effects, as glucagon is a catabolic hormone that stimulates hepatic glycogenolysis and lipolysis and increases thermogenesis. This thermogenic component may help explain the additional weight-loss magnitude observed beyond what dual incretin agonism alone achieves. However, glucagon receptor agonism also carries potential for adverse effects on glucose homeostasis, necessitating careful dose balancing and is the subject of active mechanistic research.
Retatrutide remains a research compound as of mid-2026, with Phase 3 trials ongoing under the TRIUMPH programme. It has not received marketing authorisation from the MHRA, EMA, or FDA for any indication. Its classification in the UK is accordingly as an investigational new drug, and its study is confined to authorised clinical research settings.
Discovery & Research History
Retatrutide emerged from Eli Lilly's sustained research programme into multi-receptor incretin pharmacology, building directly on the scientific and clinical precedent established by tirzepatide. Following the demonstration that dual GIP/GLP-1 agonism produced superior metabolic outcomes relative to GLP-1 monoagonism, Lilly investigators explored whether the addition of glucagon receptor co-agonism could confer further weight-reducing and energy-expenditure benefits.
The scientific rationale for including glucagon receptor agonism rested on two bodies of evidence. First, glucagon acts as an energy-mobilising hormone in the liver, promoting glycogenolysis, gluconeogenesis, and fatty acid oxidation. In the context of obesity research, glucagon agonism was hypothesised to increase basal energy expenditure by raising thermogenic activity—an effect distinct from the appetite-suppression and gastric-emptying mechanisms shared by GLP-1 and GIP agonism. Second, preclinical studies in rodent models of diet-induced obesity had shown that triple GLP-1/GIP/glucagon agonism produced additive or synergistic weight-loss effects compared to dual agonism.
The principal molecular engineering challenge was designing a single peptide capable of activating all three receptors with appropriately balanced potency—sufficient glucagon receptor agonism to augment energy expenditure while avoiding unwanted hyperglycaemia or adverse hepatic effects. Eli Lilly's medicinal chemistry team drew on structure-activity relationship data across all three receptor systems to produce LY3437943, incorporating a C-20 fatty diacid conjugate for albumin binding and once-weekly pharmacokinetics analogous to tirzepatide.
Phase 1 safety and pharmacokinetic data were generated in the late 2010s, with Phase 2 results—the pivotal NEJM 2023 paper—confirming both the remarkable efficacy signal and a gastrointestinal adverse-event profile broadly comparable to other incretin-class agents. Phase 3 TRIUMPH trials commenced in 2023 and are expected to report primary endpoints in 2025–2026.
Mechanism of Action
Retatrutide's metabolic effects arise from the simultaneous activation of three G-protein-coupled receptors involved in energy homeostasis, glucose regulation, and lipid metabolism:
GLP-1 Receptor Agonism
As with tirzepatide and semaglutide, retatrutide activates GLP-1 receptors in pancreatic beta cells, hypothalamus, brainstem, gastrointestinal tract, and other tissues. This drives glucose-dependent insulin secretion, appetite suppression through central satiety circuitry, delayed gastric emptying, and postprandial glucagon suppression. The GLP-1 receptor component provides the primary anti-hyperglycaemic anchor of the molecule.
GIP Receptor Agonism
GIP receptor co-activation in adipose tissue, pancreatic beta cells, and the central nervous system provides the same complementary and potentially synergistic benefits characterised in tirzepatide research: augmented insulin secretion, enhanced adipose-tissue partitioning effects, and additional central appetite modulation. Retatrutide's GIP agonism is designed to be balanced against its glucagon component to avoid insulin hypersecretion.
Glucagon Receptor Agonism
This is the defining feature of retatrutide relative to earlier dual agonists. Glucagon receptor activation in the liver stimulates glycogenolysis and fatty acid oxidation, increasing hepatic energy substrate turnover. In brown adipose tissue and skeletal muscle, glucagon receptor agonism promotes thermogenesis and increases basal metabolic rate. Research in mouse models of obesity has demonstrated that pharmacological glucagon receptor agonism increases whole-body oxygen consumption and reduces fat mass independently of food intake.
Energy Expenditure Augmentation
The integration of glucagon receptor agonism with dual incretin agonism is hypothesised to address the metabolic adaptation that typically accompanies caloric restriction—a downregulation of basal metabolic rate that limits long-term weight loss. By pharmacologically maintaining or increasing thermogenesis, retatrutide may overcome this adaptive response, potentially explaining the deeper and apparently non-plateauing weight-loss trajectory observed in Phase 2 data.
Hepatic Effects
The glucagon component has direct hepatic actions that may confer benefit in non-alcoholic fatty liver disease through increased hepatic lipid oxidation and reduced de novo lipogenesis. Early-phase data suggest reductions in liver fat fraction consistent with this mechanism. However, the balance between beneficial lipid-oxidation effects and the hyperglycaemic risk of glucagon-driven hepatic glucose output requires careful dose calibration.
Pancreatic Beta-Cell Effects
The combined GLP-1 and GIP receptor activation on pancreatic beta cells produces a potent insulinotropic response. In the context of concomitant glucagon receptor agonism—which carries a mild hyperglycaemic tendency—the net glycaemic effect of retatrutide is approximately neutral or modestly glucose-lowering, representing a carefully engineered pharmacological balance.
Researched Effects
- Mean body-weight reduction of approximately 24.2% from baseline at 48 weeks in Phase 2 trial at the 12 mg dose, the largest pharmacologically induced weight-loss magnitude reported in human research to date.
- Consistent dose-dependent weight loss across all doses studied (1 mg, 4 mg, 8 mg, 12 mg) in the Phase 2 trial, confirming a robust dose-response relationship.
- Weight-loss trajectory not plateau-ing by Week 48 in the 12 mg arm, suggesting potential for continued reduction with extended treatment duration.
- Meaningful reductions in fasting plasma glucose and HbA1c in participants with obesity and varying glucose tolerance status.
- Significant improvements in fasting triglycerides, LDL-cholesterol, and systolic blood pressure as secondary endpoints in Phase 2 research.
- Preliminary evidence of liver fat reduction consistent with glucagon-mediated hepatic lipid oxidation, with implications for NASH research.
- Favourable body-composition profile with the majority of weight loss attributable to fat mass rather than lean tissue, based on DXA sub-study data.
- Reduction in waist circumference indicating visceral adipose tissue mobilisation, relevant to cardiometabolic risk characterisation.
Theoretical Research Protocols
- Dosage range
- Dose-escalation schedule studied in Phase 2: 1 mg/week escalating to 4 mg, 8 mg, or 12 mg weekly maintenance over 12–24 weeks; 12 mg/week represents the highest studied dose
- Frequency
- Once weekly subcutaneous administration, consistent with the pharmacokinetic profile of the albumin-bound fatty acid conjugate
- Duration
- Phase 2 data cover 48 weeks; Phase 3 TRIUMPH trials are investigating endpoints at 72–96 weeks
- Administration routes
- Subcutaneous injection — the sole route used in all published Phase 1 and Phase 2 clinical research, Once-weekly prefilled pen delivery is the anticipated clinical presentation pending Phase 3 completion and regulatory submission
Safety Profile
Common side effects (research)
- Nausea — the most frequently reported adverse event in Phase 2 data, occurring in approximately 40–45% of participants at higher doses during escalation phases, generally transient and manageable
- Vomiting — reported in approximately 20–25% of participants at the 12 mg dose, most commonly during dose-increase weeks
- Diarrhoea — reported in approximately 15–20% of participants across dose groups
- Constipation — reported in approximately 12–15% of participants, with onset typically during maintenance phases
- Decreased appetite — universally observed and considered mechanistically integral to the therapeutic profile
- Injection-site reactions including mild erythema or transient induration
- Fatigue, reported predominantly during dose-escalation phases in Phase 2 trial data
Rare risks
- Hyperglycaemia transiently during dose initiation — a theoretical concern from the glucagon receptor component, requiring monitoring particularly in participants with impaired glucose metabolism
- Acute pancreatitis — a class-level risk across incretin-based agents; incidence in Phase 2 was low and not statistically distinguishable from background rate
- Cholelithiasis — risk elevated with rapid weight loss; observed at low frequency in Phase 2 data
- Thyroid C-cell effects — regulatory class warning for GLP-1 receptor agonists based on rodent pharmacology; human relevance unestablished
- Elevated liver enzymes — potential hepatic effects of glucagon receptor agonism require monitoring in clinical research settings
- Tachycardia — modest increases in resting heart rate consistent with incretin class effects
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 (regulatory class contraindication for GLP-1 receptor agonists)
- Active pancreatitis or significant history thereof
- Pregnancy and lactation (weight loss during pregnancy is not appropriate; no safety data available)
- Significant hepatic impairment (glucagon receptor component raises theoretical concerns in severe hepatic disease)
- Hypersensitivity to any component of the investigational peptide formulation
- Participation outside of authorised clinical trial settings — retatrutide is an IND compound and its use outside registered trials is not sanctioned
UK Regulatory Status
United Kingdom (MHRA): Retatrutide is not approved by the MHRA for any therapeutic indication as of May 2026. It is an investigational new drug (IND) undergoing Phase 3 clinical evaluation under the TRIUMPH programme. In the UK, its study is subject to Clinical Trial Authorisation (CTA) requirements under the Medicines for Human Use (Clinical Trials) Regulations 2004. It is not available as a licensed medicine and must not be supplied outside of authorised trial settings. Research-grade retatrutide peptide for in vitro or preclinical investigation may be sourced through specialist research suppliers under institutional governance, but it has no approved human indication.
European Union (EMA): Not authorised by the EMA for any indication. Phase 3 trials are ongoing across EU member states under Clinical Trial Regulation (CTR) EU No 536/2014 governance. EMA marketing authorisation application is anticipated following completion of Phase 3 TRIUMPH primary endpoints.
Notes: Retatrutide is a WADA-listed prohibited substance. No regulatory pathway for its supply for human use outside of authorised clinical trials exists in the UK or EU as of the date of this content. The striking Phase 2 efficacy data have generated significant lay media interest; potential participants in unlicensed use should be aware that Phase 3 safety characterisation is incomplete.
Related research resources
Key Research Studies
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial
The pivotal Phase 2 dose-ranging trial published in The Lancet (2023) enrolling 281 adults with type 2 diabetes. Retatrutide at 12 mg weekly produced HbA1c reductions of 2.02 percentage points and weight reductions of approximately 16.9% at 36 weeks, compared to 0.39% with placebo. Dose-dependent effects were confirmed across all dose groups with a manageable gastrointestinal safety profile.
Read sourceRetatrutide for Obesity — A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
The primary obesity Phase 2 trial published in The New England Journal of Medicine (2023) enrolling 338 adults with obesity or overweight and comorbidities. Participants receiving 12 mg retatrutide achieved a mean weight reduction of 24.2% at 48 weeks versus 2.1% with placebo. Weight loss had not reached a plateau at trial completion, and body-composition analyses confirmed predominantly fat-mass reduction. The authors concluded that the triagonist mechanism may produce greater weight loss than dual incretin agonism.
Read sourceTriple Hormone Receptor Agonism: Preclinical Characterisation of the Glucagon Component's Contribution to Weight Loss
Preclinical mechanistic studies underpinning the retatrutide programme demonstrated that selective glucagon receptor agonism in rodent models of diet-induced obesity increased whole-body oxygen consumption, hepatic lipid oxidation, and brown adipose tissue thermogenesis. When combined with GIP and GLP-1 receptor co-agonism, additive reductions in body weight and fat mass were observed that exceeded dual agonism controls, providing the mechanistic rationale for the clinical triagonist programme.
TRIUMPH Phase 3 Programme — Trial Design and Rationale
Publication describing the design of the Phase 3 TRIUMPH trials investigating retatrutide in adults with obesity (without diabetes), adults with obesity and type 2 diabetes, and adolescents with obesity. Primary endpoints at 72 weeks include percentage change in body weight and the proportion achieving ≥5% reduction. Secondary endpoints include cardiometabolic risk markers, sleep apnoea measures, and liver histology in NASH sub-studies.
Frequently Asked Questions
What makes retatrutide different from tirzepatide?
Retatrutide adds glucagon receptor agonism to the GIP and GLP-1 receptor agonism that defines tirzepatide. The glucagon component is hypothesised to increase basal energy expenditure and thermogenesis—mechanisms that complement the appetite suppression and incretin effects of GIP/GLP-1 agonism. Phase 2 data suggest this triple mechanism produces approximately 1.5–2 additional percentage points of weight loss versus tirzepatide at comparable timepoints, though direct head-to-head data are not yet available from Phase 3.
What weight loss has been observed with retatrutide in Phase 2 research?
In the Phase 2 NEJM 2023 trial, participants with obesity receiving 12 mg retatrutide weekly achieved a mean body-weight reduction of approximately 24.2% at 48 weeks. Crucially, the weight-loss trajectory had not plateaued by Week 48 in the highest-dose group, suggesting that longer treatment might yield further reductions. This represents the largest pharmacologically induced weight-loss result published in a human clinical trial as of 2026.
Is retatrutide available in the UK?
No. Retatrutide is not approved by the MHRA or any regulatory authority as of May 2026. It remains an investigational new drug undergoing Phase 3 TRIUMPH trials. It is not legally available outside of authorised clinical research settings in the UK. Procurement through unregulated channels would contravene the Human Medicines Regulations 2012 and carries significant safety risks given incomplete Phase 3 characterisation.
Why does retatrutide include glucagon receptor agonism?
Glucagon is a catabolic hormone that promotes hepatic lipid oxidation, glycogenolysis, and thermogenesis. Its receptor agonism is included to increase basal energy expenditure—a mechanism absent from GLP-1 and GIP agonism, which primarily reduce energy intake. Preclinical research demonstrated additive weight-loss effects when glucagon agonism was combined with dual GIP/GLP-1 agonism. The principal design challenge was calibrating the glucagon component to provide energy expenditure benefits without inducing significant hyperglycaemia.
What are the main safety concerns with retatrutide?
The Phase 2 safety profile was broadly similar to other incretin-class agents: the most common adverse events were gastrointestinal (nausea, vomiting, diarrhoea, constipation), predominantly during dose-escalation phases. The glucagon receptor component introduces theoretical concerns around transient hyperglycaemia and hepatic effects that require monitoring. Full characterisation of the long-term safety profile awaits Phase 3 data. The thyroid C-cell class warning applicable to GLP-1 receptor agonists is also applicable.
When might retatrutide receive regulatory approval?
Phase 3 TRIUMPH trials commenced in 2023 with primary endpoints at 72 weeks. Based on typical regulatory timelines, a New Drug Application or marketing authorisation application to the FDA, EMA, and MHRA might be submitted in 2025–2026, with potential approval decisions in 2026–2027, subject to trial results and regulatory review timelines. These projections are inherently uncertain.
How does retatrutide affect energy expenditure compared to GLP-1 agonists?
This remains an active area of research. Preclinical data indicate that the glucagon receptor component increases basal metabolic rate through thermogenesis in brown adipose tissue and increased hepatic lipid oxidation. Human mechanistic substudies from the Phase 2 programme using indirect calorimetry are expected to quantify any increase in resting energy expenditure, which would distinguish retatrutide's mechanism from the predominantly food-intake-reducing mechanism of GLP-1 monoagonists.